Multiple roles of ANO6 in tumors, molecular mechanism and its potential therapeutic value

IF 2.2 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2025-09-26 DOI:10.1016/j.bbrep.2025.102230

Ao Chen , Chenyu Yang , Jin Wang

{"title":"Multiple roles of ANO6 in tumors, molecular mechanism and its potential therapeutic value","authors":"Ao Chen , Chenyu Yang , Jin Wang","doi":"10.1016/j.bbrep.2025.102230","DOIUrl":null,"url":null,"abstract":"<div><div>Anoctamin 6 (ANO6/TMEM16F) is a calcium-activated ion channel and phospholipid disruptor that plays a key role in maintaining cellular homeostasis. This review focuses on the role of ANO6 in various cancers. On one hand, ANO6 is highly expressed in pancreatic cancer, gastric cancer, and glioma, while its expression is downregulated in breast cancer, prostate cancer, cervical cancer, and ovarian cancer. This indicates its functional diversity across different cancer types, reflecting the complex regulatory mechanisms of ANO6 in the tumor microenvironment. In pancreatic cancer, ANO6 is highly expressed, and it promotes pancreatic cancer metastasis through the ERK signaling pathway. In melanoma, ANO6 is closely associated with poor patient prognosis, clinical-pathological characteristics, tumor immunity, and tumor heterogeneity. In breast cancer, ANO6 is a ferroptosis gene associated with prognosis, and its low expression is linked to poor outcomes, making it a key independent predictor of overall survival in breast cancer patients. Additionally, the relationship between ANO6 and immune cells highlights its potential role in cancer immune surveillance and therapy. Finally, we found that ANO6 may regulate immune cell exhaustion in the tumor microenvironment by influencing macrophage polarization and T cell recruitment and activation. This review highlights the diverse roles of ANO6 in different cancers and its potential as a diagnostic and therapeutic tool. Future studies should address the mechanistic details of ANO6 involvement in cancer, validate its clinical utility, and explore its therapeutic potential in combination with existing therapies.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"44 ","pages":"Article 102230"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580825003176","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Anoctamin 6 (ANO6/TMEM16F) is a calcium-activated ion channel and phospholipid disruptor that plays a key role in maintaining cellular homeostasis. This review focuses on the role of ANO6 in various cancers. On one hand, ANO6 is highly expressed in pancreatic cancer, gastric cancer, and glioma, while its expression is downregulated in breast cancer, prostate cancer, cervical cancer, and ovarian cancer. This indicates its functional diversity across different cancer types, reflecting the complex regulatory mechanisms of ANO6 in the tumor microenvironment. In pancreatic cancer, ANO6 is highly expressed, and it promotes pancreatic cancer metastasis through the ERK signaling pathway. In melanoma, ANO6 is closely associated with poor patient prognosis, clinical-pathological characteristics, tumor immunity, and tumor heterogeneity. In breast cancer, ANO6 is a ferroptosis gene associated with prognosis, and its low expression is linked to poor outcomes, making it a key independent predictor of overall survival in breast cancer patients. Additionally, the relationship between ANO6 and immune cells highlights its potential role in cancer immune surveillance and therapy. Finally, we found that ANO6 may regulate immune cell exhaustion in the tumor microenvironment by influencing macrophage polarization and T cell recruitment and activation. This review highlights the diverse roles of ANO6 in different cancers and its potential as a diagnostic and therapeutic tool. Future studies should address the mechanistic details of ANO6 involvement in cancer, validate its clinical utility, and explore its therapeutic potential in combination with existing therapies.

查看原文本刊更多论文

ANO6在肿瘤中的多重作用、分子机制及其潜在的治疗价值

Anoctamin 6 （ANO6/TMEM16F）是一种钙激活离子通道和磷脂干扰物，在维持细胞稳态中起关键作用。本文就ANO6在各种癌症中的作用作一综述。ANO6一方面在胰腺癌、胃癌、胶质瘤中高表达，而在乳腺癌、前列腺癌、宫颈癌、卵巢癌中表达下调。这表明其在不同肿瘤类型中的功能多样性，反映了ANO6在肿瘤微环境中的复杂调控机制。在胰腺癌中，ANO6高表达，通过ERK信号通路促进胰腺癌转移。在黑色素瘤中，ANO6与患者预后差、临床病理特征、肿瘤免疫和肿瘤异质性密切相关。在乳腺癌中，ANO6是一个与预后相关的铁下垂基因，其低表达与预后不良相关，使其成为乳腺癌患者总生存率的关键独立预测因子。此外，ANO6与免疫细胞之间的关系突出了其在癌症免疫监测和治疗中的潜在作用。最后，我们发现ANO6可能通过影响巨噬细胞极化和T细胞募集和激活来调节肿瘤微环境中的免疫细胞衰竭。这篇综述强调了ANO6在不同癌症中的不同作用及其作为诊断和治疗工具的潜力。未来的研究应该解决ANO6参与癌症的机制细节，验证其临床应用，并探索其与现有疗法联合的治疗潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.